Journal
Blood Advances
Publication Date
4-12-2022
Volume
6
Issue
7
First Page
2035
Last Page
2044
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2021006844
Rights and Permissions
Alderuccio JP, Arcaini L, Watkins MP, Beaven AW, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert AB, Olszewski AJ, Kim SH, Hess B, Gaballa S, Ayyappan S, Castillo JJ, Argnani L, Voorhees TJ, Saba R, Chowdhury SM, Vargas F, Reis IM, Kwon D, Alexander JS, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link BK, Logothetis CN, Herrera AF, Friedberg JW, Kahl BS, Luminari S, Zinzani PL, Lossos IS. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022 Apr 12;6(7):2035-2044. doi.org/10.1182/bloodadvances.2021006844 © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Alderuccio, Juan Pablo; Watkins, Marcus P; Saba, Raya; Kahl, Brad S; and et al, "An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma." Blood Advances. 6, 7. 2035 - 2044. (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11788
